Pub Date : 2007-10-30DOI: 10.2217/1745509X.3.5.647
G. Lemack
Elderly patients with diabetes appear to be particularly susceptible to urological complications. Diabetes impacts the urological quality of life as bothersome urinary symptoms (including incontinence) are clearly associated with the development and progression of diabetes. When recognized early, many symptoms can be treated through a combination of behavioral and pharmacological management. Without attention to the early signs of urinary symptoms in elderly patients, significant urological dysfunction may occur, leading to morbidity and often-preventable symptomatic deterioration.
{"title":"Lower urinary tract dysfunction in the diabetic elderly","authors":"G. Lemack","doi":"10.2217/1745509X.3.5.647","DOIUrl":"https://doi.org/10.2217/1745509X.3.5.647","url":null,"abstract":"Elderly patients with diabetes appear to be particularly susceptible to urological complications. Diabetes impacts the urological quality of life as bothersome urinary symptoms (including incontinence) are clearly associated with the development and progression of diabetes. When recognized early, many symptoms can be treated through a combination of behavioral and pharmacological management. Without attention to the early signs of urinary symptoms in elderly patients, significant urological dysfunction may occur, leading to morbidity and often-preventable symptomatic deterioration.","PeriodicalId":88353,"journal":{"name":"Aging health","volume":"3 1","pages":"647-651"},"PeriodicalIF":0.0,"publicationDate":"2007-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/1745509X.3.5.647","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68187422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2007-10-30DOI: 10.2217/1745509X.3.5.585
B. Hammond
Evaluation of: Richer S, Devenport J, Lang JC: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry 78, 213–219 (2007) [1]. The Lutein Antioxidant Supplementation Trial (LAST) was conducted to evaluate whether supplementation of an antioxidant cocktail, including, most notably, the carotenoid lutein, would improve visual function in patients with early age-related macular degeneration. Age-related macular degeneration is the most common form of blindness in the USA and supplementation did, in fact, improve many of the visual functions tested in LAST. These visual improvements were strongly linked to increases in the amount of lutein and zeaxanthin within the retina (termed macular pigment) that resulted from the intervention. LAST II was therefore designed to determine what specific characteristics identified those patients whose retinas responded most strongly to the supplement...
{"title":"The retina as a nutritionally responsive tissue","authors":"B. Hammond","doi":"10.2217/1745509X.3.5.585","DOIUrl":"https://doi.org/10.2217/1745509X.3.5.585","url":null,"abstract":"Evaluation of: Richer S, Devenport J, Lang JC: Differential temporal responses of macular pigment optical density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. Optometry 78, 213–219 (2007) [1]. The Lutein Antioxidant Supplementation Trial (LAST) was conducted to evaluate whether supplementation of an antioxidant cocktail, including, most notably, the carotenoid lutein, would improve visual function in patients with early age-related macular degeneration. Age-related macular degeneration is the most common form of blindness in the USA and supplementation did, in fact, improve many of the visual functions tested in LAST. These visual improvements were strongly linked to increases in the amount of lutein and zeaxanthin within the retina (termed macular pigment) that resulted from the intervention. LAST II was therefore designed to determine what specific characteristics identified those patients whose retinas responded most strongly to the supplement...","PeriodicalId":88353,"journal":{"name":"Aging health","volume":"3 1","pages":"585-588"},"PeriodicalIF":0.0,"publicationDate":"2007-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/1745509X.3.5.585","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68187757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2007-10-30DOI: 10.2217/1745509X.3.5.663
A. Tsimberidou, E. Estey
In recent years, major advances have been made in the treatment of acute myeloid leukemia (AML) in younger patients, but the prognosis for elderly AML patients remains poor. This review focuses on current and emerging data on the treatment of AML in the elderly. Most elderly patients are not considered for induction therapy. Cytarabine and anthracycline combination therapies induce remission in up to 50% of cases of newly diagnosed AML, and the median survival duration ranges between 5 and 10 months. Targeted therapies such as monoclonal antibodies (gemtuzumab ozogamicin), farnesyltransferase inhibitors (tipifarnib), tyrosine kinase inhibitors (lestaurtinib) and hypomethylating agents (decitabine and valproic acid) are being investigated in elderly patients with AML. Autologous and reduced-intensity allogeneic stem cell transplantation has been used in selected patients.
{"title":"Treatment of older patients with acute myeloid leukemia","authors":"A. Tsimberidou, E. Estey","doi":"10.2217/1745509X.3.5.663","DOIUrl":"https://doi.org/10.2217/1745509X.3.5.663","url":null,"abstract":"In recent years, major advances have been made in the treatment of acute myeloid leukemia (AML) in younger patients, but the prognosis for elderly AML patients remains poor. This review focuses on current and emerging data on the treatment of AML in the elderly. Most elderly patients are not considered for induction therapy. Cytarabine and anthracycline combination therapies induce remission in up to 50% of cases of newly diagnosed AML, and the median survival duration ranges between 5 and 10 months. Targeted therapies such as monoclonal antibodies (gemtuzumab ozogamicin), farnesyltransferase inhibitors (tipifarnib), tyrosine kinase inhibitors (lestaurtinib) and hypomethylating agents (decitabine and valproic acid) are being investigated in elderly patients with AML. Autologous and reduced-intensity allogeneic stem cell transplantation has been used in selected patients.","PeriodicalId":88353,"journal":{"name":"Aging health","volume":"3 1","pages":"663-673"},"PeriodicalIF":0.0,"publicationDate":"2007-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/1745509X.3.5.663","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68187471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2007-10-30DOI: 10.2217/1745509X.3.5.595
S. Martin-Schild, J. Grotta
The greatest impact on the delivery of stroke treatment has been the movement to implement stroke centers and the expansion of acute stroke care through telemedicine. Access to vascular neurologists is likely to increase the rate of thrombolytic treatment for ischemic stroke and lessen the rising economic burden of this disease. The advancements in stroke research of today portend the future of stroke treatment. We anticipate implementation of effective neuroprotective agents, improvements in diagnostic neuroimaging and endovascular techniques, identification of the genomics of stroke-prone individuals and genetic engineering to reduce predetermined risk. We expect advancements in neurorehabilitation that will reduce dependency.
{"title":"Future of stroke treatment","authors":"S. Martin-Schild, J. Grotta","doi":"10.2217/1745509X.3.5.595","DOIUrl":"https://doi.org/10.2217/1745509X.3.5.595","url":null,"abstract":"The greatest impact on the delivery of stroke treatment has been the movement to implement stroke centers and the expansion of acute stroke care through telemedicine. Access to vascular neurologists is likely to increase the rate of thrombolytic treatment for ischemic stroke and lessen the rising economic burden of this disease. The advancements in stroke research of today portend the future of stroke treatment. We anticipate implementation of effective neuroprotective agents, improvements in diagnostic neuroimaging and endovascular techniques, identification of the genomics of stroke-prone individuals and genetic engineering to reduce predetermined risk. We expect advancements in neurorehabilitation that will reduce dependency.","PeriodicalId":88353,"journal":{"name":"Aging health","volume":"3 1","pages":"595-600"},"PeriodicalIF":0.0,"publicationDate":"2007-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/1745509X.3.5.595","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68187360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2007-10-30DOI: 10.2217/1745509X.3.5.625
Keith M Bellizzi, J. Rowland
Men and women aged over 65 years represent 60% of the 10.8 million cancer survivors in the US. The proportion of older cancer survivors will increase significantly with the aging of the population. Unlike younger survivors, the experience of cancer in those diagnosed with cancer as older adults is often superimposed on existing health conditions, which disproportionately affect the elderly population. Understanding the extent to which having cancer contributes to decrements in physical, mental and social function, above and beyond the influence of other chronic health conditions and normative aging, will be critical to the long-term care of older cancer survivors. In this article, we review the extant research on the influence of comorbidity, symptoms and age on the health and functioning of older survivors following treatment for cancer. Future research directions are highlighted, along with several approaches to advancing the field, including the identification of strategies to deliver care to the older population after cancer treatment, changing how we view older adults and consider their health, and, finally, finding systematic approaches to monitor the impact of cancer on older survivors’ health and wellbeing. One of the great medical achievements of the latter part of the last century was the ability to turn cancer, once an almost uniformly fatal illness, into a curable disease for some – in particular our
{"title":"Role of comorbidity, symptoms and age in the health of older survivors following treatment for cancer","authors":"Keith M Bellizzi, J. Rowland","doi":"10.2217/1745509X.3.5.625","DOIUrl":"https://doi.org/10.2217/1745509X.3.5.625","url":null,"abstract":"Men and women aged over 65 years represent 60% of the 10.8 million cancer survivors in the US. The proportion of older cancer survivors will increase significantly with the aging of the population. Unlike younger survivors, the experience of cancer in those diagnosed with cancer as older adults is often superimposed on existing health conditions, which disproportionately affect the elderly population. Understanding the extent to which having cancer contributes to decrements in physical, mental and social function, above and beyond the influence of other chronic health conditions and normative aging, will be critical to the long-term care of older cancer survivors. In this article, we review the extant research on the influence of comorbidity, symptoms and age on the health and functioning of older survivors following treatment for cancer. Future research directions are highlighted, along with several approaches to advancing the field, including the identification of strategies to deliver care to the older population after cancer treatment, changing how we view older adults and consider their health, and, finally, finding systematic approaches to monitor the impact of cancer on older survivors’ health and wellbeing. One of the great medical achievements of the latter part of the last century was the ability to turn cancer, once an almost uniformly fatal illness, into a curable disease for some – in particular our","PeriodicalId":88353,"journal":{"name":"Aging health","volume":"3 1","pages":"625-635"},"PeriodicalIF":0.0,"publicationDate":"2007-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/1745509X.3.5.625","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68187667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2007-10-30DOI: 10.2217/1745509X.3.5.589
M. Saint-Hubert, C. Swine
This article presents the current status of the definitions of frailty. The theoretical definitions are summarized, and the main elements of these definitions are developed. Frailty as a geriatric syndrome is briefly put into debate, and a model showing the relationships between the factors involved and the outcomes of frailty is proposed. The dynamics of functional decline and geriatric syndromes are put into the perspective of different stages of frailty. For the practical use of the concept, the operational definitions and the principal tools, indices and scales from the literature are briefly described, along with their main characteristics.
{"title":"Evolving definitions of frailty","authors":"M. Saint-Hubert, C. Swine","doi":"10.2217/1745509X.3.5.589","DOIUrl":"https://doi.org/10.2217/1745509X.3.5.589","url":null,"abstract":"This article presents the current status of the definitions of frailty. The theoretical definitions are summarized, and the main elements of these definitions are developed. Frailty as a geriatric syndrome is briefly put into debate, and a model showing the relationships between the factors involved and the outcomes of frailty is proposed. The dynamics of functional decline and geriatric syndromes are put into the perspective of different stages of frailty. For the practical use of the concept, the operational definitions and the principal tools, indices and scales from the literature are briefly described, along with their main characteristics.","PeriodicalId":88353,"journal":{"name":"Aging health","volume":"3 1","pages":"589-593"},"PeriodicalIF":0.0,"publicationDate":"2007-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/1745509X.3.5.589","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68187806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2007-10-30DOI: 10.2217/1745509X.3.5.601
B. Zarowitz
Drug therapy mistreatment, undertreatment and overtreatment of older persons are prevalent. Given the pharmacokinetic and pharmacodynamic changes in seniors, the risk versus benefit of treatment should be weighed before implementing pharmacotherapy. Clinicians cannot rely exclusively on high-quality scientific evidence to make treatment decisions, given the paucity of evidence-based approaches to care in this population. A growing emphasis is needed, by pharmaceutical companies and independent researchers, to understand the value of treatment in older persons. An examination of the evidence for treatment of depression Alzheimer’s disease, behavioral symptoms of dementia and depression in older persons is presented. Further research in this growing and highly vulnerable population is needed to guide informed treatment decisions.
{"title":"Limits of evidence-based medicine in older adults","authors":"B. Zarowitz","doi":"10.2217/1745509X.3.5.601","DOIUrl":"https://doi.org/10.2217/1745509X.3.5.601","url":null,"abstract":"Drug therapy mistreatment, undertreatment and overtreatment of older persons are prevalent. Given the pharmacokinetic and pharmacodynamic changes in seniors, the risk versus benefit of treatment should be weighed before implementing pharmacotherapy. Clinicians cannot rely exclusively on high-quality scientific evidence to make treatment decisions, given the paucity of evidence-based approaches to care in this population. A growing emphasis is needed, by pharmaceutical companies and independent researchers, to understand the value of treatment in older persons. An examination of the evidence for treatment of depression Alzheimer’s disease, behavioral symptoms of dementia and depression in older persons is presented. Further research in this growing and highly vulnerable population is needed to guide informed treatment decisions.","PeriodicalId":88353,"journal":{"name":"Aging health","volume":"3 1","pages":"601-610"},"PeriodicalIF":0.0,"publicationDate":"2007-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/1745509X.3.5.601","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68187374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2007-10-30DOI: 10.2217/1745509X.3.5.611
A. Dawn, M. E. Dawn, G. Yosipovitch
Psoriasis is one of the most common chronic skin diseases, and unprecedented increases in the elderly population will make diagnosis and management of geriatric psoriasis increasingly important. Management of psoriasis in the elderly requires consideration of several important factors. Many commonly prescribed drugs can precipitate psoriasis or aggravate pre-existing psoriasis. In addition, elderly patients are at increased risk of adverse drug reactions due to polypharmacy, adverse drug–drug interactions, adverse drug–disease interactions, incorrect use of medication and concomitant comorbidities. Psoriasis is a highly variable disease that requires individualized treatment. The major classes of topical medications include topical corticosteroids, coal tar preparations, calcipotriol, tazarotene and salicylic acid. Phototherapy, including narrowband ultraviolet B, photochemotherapy, psoralen ultraviolet A and excimer laser treatment, can be effective in properly selected patients. Systemic therapy for pso...
{"title":"Psoriasis in the elderly","authors":"A. Dawn, M. E. Dawn, G. Yosipovitch","doi":"10.2217/1745509X.3.5.611","DOIUrl":"https://doi.org/10.2217/1745509X.3.5.611","url":null,"abstract":"Psoriasis is one of the most common chronic skin diseases, and unprecedented increases in the elderly population will make diagnosis and management of geriatric psoriasis increasingly important. Management of psoriasis in the elderly requires consideration of several important factors. Many commonly prescribed drugs can precipitate psoriasis or aggravate pre-existing psoriasis. In addition, elderly patients are at increased risk of adverse drug reactions due to polypharmacy, adverse drug–drug interactions, adverse drug–disease interactions, incorrect use of medication and concomitant comorbidities. Psoriasis is a highly variable disease that requires individualized treatment. The major classes of topical medications include topical corticosteroids, coal tar preparations, calcipotriol, tazarotene and salicylic acid. Phototherapy, including narrowband ultraviolet B, photochemotherapy, psoralen ultraviolet A and excimer laser treatment, can be effective in properly selected patients. Systemic therapy for pso...","PeriodicalId":88353,"journal":{"name":"Aging health","volume":"3 1","pages":"611-623"},"PeriodicalIF":0.0,"publicationDate":"2007-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/1745509X.3.5.611","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68187657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2007-10-30DOI: 10.2217/1745509X.3.5.575
E. Inelmen, E. Inelmen
The marked increase in life expectancy witnessed in the last few decades has turned the topic of aging into an extremely important issue. Consequently, priority should be given in the future to developing the new framework needed for a ‘successful aging’ research program. This article focuses on finding evidence for the real meaning of successful aging in the conviction that it is important to thoroughly discuss the related issues and recommend new policies to implement in public-health circles. To this end, we provide some indicators on how to age without growing old. We would all agree that ‘aging’ is becoming an increasingly important issue for policy makers all over the world. Unfortunately, nothing can be done to delay, stop or reverse the human aging process [1], despite the promise of anti-aging products (intended to make us look younger) that may well succeed in changing our appearance, but do not change our chronological age. In order to provide recommendations on healthy aging for healthcare professionals, we first need to answer some relevant questions. For instance: • What do aging and being old really mean? • Is it possible to live to be 120 years and still be healthy? • Is being healthy synonymous with successful aging? • Can we say that healthy aging is the same as successful aging? • What exactly do we mean by successful aging? This may not be the whole list of the issues that need to be considered. Nevertheless, encouraged by previous work on the subject [2], in the following sections we attempt to provide some answers to these crucial questions. The implementation of these new practices will no doubt
{"title":"Aging without becoming old: myth or reality?","authors":"E. Inelmen, E. Inelmen","doi":"10.2217/1745509X.3.5.575","DOIUrl":"https://doi.org/10.2217/1745509X.3.5.575","url":null,"abstract":"The marked increase in life expectancy witnessed in the last few decades has turned the topic of aging into an extremely important issue. Consequently, priority should be given in the future to developing the new framework needed for a ‘successful aging’ research program. This article focuses on finding evidence for the real meaning of successful aging in the conviction that it is important to thoroughly discuss the related issues and recommend new policies to implement in public-health circles. To this end, we provide some indicators on how to age without growing old. We would all agree that ‘aging’ is becoming an increasingly important issue for policy makers all over the world. Unfortunately, nothing can be done to delay, stop or reverse the human aging process [1], despite the promise of anti-aging products (intended to make us look younger) that may well succeed in changing our appearance, but do not change our chronological age. In order to provide recommendations on healthy aging for healthcare professionals, we first need to answer some relevant questions. For instance: • What do aging and being old really mean? • Is it possible to live to be 120 years and still be healthy? • Is being healthy synonymous with successful aging? • Can we say that healthy aging is the same as successful aging? • What exactly do we mean by successful aging? This may not be the whole list of the issues that need to be considered. Nevertheless, encouraged by previous work on the subject [2], in the following sections we attempt to provide some answers to these crucial questions. The implementation of these new practices will no doubt","PeriodicalId":88353,"journal":{"name":"Aging health","volume":"3 1","pages":"575-580"},"PeriodicalIF":0.0,"publicationDate":"2007-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/1745509X.3.5.575","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68187745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2007-10-30DOI: 10.2217/1745509X.3.5.637
Liam P. Ryan, Alexander R Opotowski, J. Gorman, R. Gorman
Mitral regurgitation is a clinically significant and increasingly common problem in the elderly population. Traditionally, mitral valve surgery has been considered high risk in this population, with a relatively high reported mortality and disappointing long-term survival. Consequently, mitral valve surgery has been reserved for severely symptomatic patients or avoided altogether. However, recently reported improvements in operative outcomes in both younger and elderly patient populations suggest that such a restrictive approach to operative intervention is not necessary. In this current manuscript, we discuss the various etiologies of mitral regurgitation in the elderly population as well as a rational approach to risk stratification and the indications for surgical intervention. Furthermore, we discuss the results of several recent studies that deal with the question of operative outcomes in the elderly population, and conclude with our recommendations for managing this challenging clinical problem.
{"title":"Management of mitral regurgitation in the elderly patient","authors":"Liam P. Ryan, Alexander R Opotowski, J. Gorman, R. Gorman","doi":"10.2217/1745509X.3.5.637","DOIUrl":"https://doi.org/10.2217/1745509X.3.5.637","url":null,"abstract":"Mitral regurgitation is a clinically significant and increasingly common problem in the elderly population. Traditionally, mitral valve surgery has been considered high risk in this population, with a relatively high reported mortality and disappointing long-term survival. Consequently, mitral valve surgery has been reserved for severely symptomatic patients or avoided altogether. However, recently reported improvements in operative outcomes in both younger and elderly patient populations suggest that such a restrictive approach to operative intervention is not necessary. In this current manuscript, we discuss the various etiologies of mitral regurgitation in the elderly population as well as a rational approach to risk stratification and the indications for surgical intervention. Furthermore, we discuss the results of several recent studies that deal with the question of operative outcomes in the elderly population, and conclude with our recommendations for managing this challenging clinical problem.","PeriodicalId":88353,"journal":{"name":"Aging health","volume":"3 1","pages":"637-646"},"PeriodicalIF":0.0,"publicationDate":"2007-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/1745509X.3.5.637","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68187414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：